VANCOUVER, BC / ACCESSWIRE / August 31, 2016 / Jaxon Minerals Inc. (TSXV: JAX) has cancelled 205,000 existing stock options and is granting a total of 1,840,000 new stock options to directors, officers and consultants.

The options granted are for a period of two (2) years, expiring on August 31, 2018 at a price of 7 cents.

ON BEHALF OF THE BOARD OF DIRECTORS
JAXON MINERALS INC.

“Leif Smither”
Leif Smither, President.

For further information regarding Jaxon Minerals Inc., please contact Leif Smither at 604-608-0400, Toll free: 1-877-608-0007.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Jaxon Minerals Inc.

ReleaseID: 444611

Lead Candidate GNbAc1 Targets the potential underlying cause of Multiple Sclerosis; Report Available here: www.lifescicapital.com/equity-research/geneuro/

NEW YORK, NY / ACCESSWIRE / August 31, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of GeNeuro (Euronext Paris: GNRO.PA), a Swiss company developing treatments for autoimmune conditions caused by the pathogenic expression of human endogenous retroviral (HERV) genetic elements.

GeNeuro’s lead candidate is GNbAc1, a monoclonal antibody against the envelope protein of the multiple sclerosis associated retrovirus (MSRV-Env). MSRV-Env is a HERV element that is silent in healthy people but ubiquitously expressed in multiple sclerosis (MS) lesions. MSRV-Env has been shown to activate the toll-like receptor 4 (TLR4) pathway, a component of the innate immune system, and has been proposed as a causal trigger to the neuroinflammation and neurodegeneration seen in MS. GNbAC1 may prevent the immune activation thought to set the disease process in motion, reflecting a novel treatment strategy that could be highly disruptive to the MS treatment landscape. GeNeuro is currently evaluating GNbAC1 in a Phase IIb study with funding from their partner Servier and expects to report preliminary results in the fourth quarter of 2017.

The existing scientific literature suggests that a drug with anti-HERV activity may be effective in many autoimmune conditions in addition to MS, such as chronic inflammatory demyelinating polyneuropathy (CIDP) and type 1 diabetes (T1D). GeNeuro’s anti-HERV platform and expertise in HERV-mediated disease could allow for GeNeuro to develop disruptive therapies for these indications. The Company also has a preclinical candidate against HERV-K that is in development for amyotrophic lateral sclerosis (ALS).

In a 36 page Initiation Report, LifeSci Capital explains the Company’s novel treatment strategy for MS, the potential complications with existing therapies resulting from broad suppression of the immune system, and the large market opportunity for disease-modifying MS therapies.

Dr. Sherman’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on GeNeuro as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

David Sherman, Ph.D.
Phone: (212) 915-2570
Email: dsherman@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 444609

LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Concordia International Corp. (“Concordia” or the “Company”) (Nasdaq: CXRX) concerning possible violations of federal securities laws between November 12, 2015 and August 12, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the October 14, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, the Company made false and misleading statements and/or failed to disclose: that Concordia was facing increased market competition against its drug Donnatal and other products; that the Company’s financial results would suffer and thus it would be forced to suspend its dividend; and that as a result of the above, Concordia’s statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis.

On August 12, 2016, Concordia announced that it would lower its 2016 guidance due to unexpected competition and current foreign exchange rates. The Company also announced that CFO Adrian de Saldanha was leaving, and that the Board unanimously agreed to suspend the Company’s quarterly dividend. When this news was released to the public, shares of Concordia dropped in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444605

IRVINE, CA / ACCESSWIRE / August 31, 2016 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit has been filed against Emergent BioSolutions, Inc. (“Emergent” or the “Company”) (NYSE: EBS). Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.

If you purchased Emergent shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Emergent issued materially false and misleading statements about its business and financial prospects, specifically relating to future lucrative contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax. These statements caused the Company’s common stock to trade at artificially inflated prices, which certain defendants sold. On June 22, 2016, Emergent announced that the U.S. government issued notices that it would be purchasing fewer doses than investors were led to believe, and that when newer and faster next-generation antrax vaccines are developed and approved, the Company would lose its procurement contract exclusivity. When this news was released to the public, shares of the stock decreased in value, causing investors harm.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 444604

LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against The GEO Group, Inc. (“GEO” or the “Company”) (NYSE: GEO) concerning possible violations of federal securities laws between March 1, 2012 and August 17, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the October 24, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, GEO made false and/or misleading statements and/or failed to disclose: that GEO’s facilities lacked adequate safety and security standards and were less efficient at offering correctional services than the Federal Bureau of Prisons’ (“BOP”) facilities; that the Company’s rehabilitative services for inmates were less effective than the BOP’s services; that the U.S. Department of Justice (“DOJ”) was unlikely to renew and/or extend its contracts with GEO; and that as a result of the above, GEO’s public statements were materially false and misleading at all relevant times. On August 18, 2016, Deputy Attorney General Sally Yates announced that the DOJ decided to stop using private prisons, since they are less safe and less effective than federal government-run prisons. When this news was disclosed, shares of GEO dropped in value.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444602

LOS ANGELES, CA / ACCESSWIRE / August 31, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Signet Jewelers Limited (“Signet” or the “Company”) (NYSE: SIG) concerning possible violations of federal securities laws between January 7, 2016 and June 3, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the October 24, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, Signet made false and/or misleading statements and/or failed to disclose: that the Company was having difficulty ensuring the safety of customers’ jewelry while in the custody of Signet’s brands; that employees at stores under at least one of Signet’s brands (Kay) were swapping customers’ stones for less valuable stones; that the Company was experiencing a decrease in customer confidence; that the Company was facing increasing competitive pressures; that Signet’s financial performance was being negatively impacted; and that as a result of the above, the Company’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When this information was disclosed, shares of Signet decreased in value, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 444601

IRVINE, CA / ACCESSWIRE / August 31, 2016 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit was filed against Global Digital Solutions Inc. (“Global Digital” or the “Company”) (OTC: GDSI). Investors who purchased or otherwise acquired shares between October 8, 2013 and August 12, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the October 24, 2016 lead plaintiff motion deadline.

If you purchased shares of Global Digital during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Global Digital made false and/or misleading statements and/or failed to disclose that: Airtronic USA, Inc.’s original equipment manufacturer supplier agreement that Global Digital disclosed in its October 2013 press releases did not exist; that the Company failed to remove misleading statements from its website even after repeated requests to do so from the CEO of Airtronic; that Global Digital lacked a reasonable basis for its revenue projection for 2014; that the Company had no credible financing to acquire any company; that Global Digital received various communications indicating Remington Outdoor Company, Inc. had no interest in Global Digital’s unsolicited acquisition offer; that Remington had already rejected Global Digital’s offer on several occasions; and that as a result of the above, the Company’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When this news was announced, Global Digital shares fell in value, causing investors harm.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 444600

IRVINE, CA / ACCESSWIRE / August 31, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Power Solutions International, Inc. (“Power Solutions” or the “Company”) (Nasdaq: PSIX). Investors who purchased or otherwise acquired shares between May 8, 2015 and August 15, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the October 21, 2016 lead plaintiff motion deadline.

If you purchased shares of Power Solutions during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Power Solutions made false and misleading statements and/or failed to disclose that: the Company inappropriately recognized revenue for certain transactions; that the Company lacked adequate internal controls over financial reporting; and that as a result of the above, Power Solutions’ public statements were materially false and misleading at all relevant times. On August 15, 2016, the Company announced that it would delay filing its Form 10-Q for the quarter ending June 30, 2016 because its financial statements were incomplete due to possible problems with certain transactions involving revenue recognition. When this news was released, shares of Power Solutions fell in value.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 444598